Provided by Tiger Fintech (Singapore) Pte. Ltd.

ACADIA Pharmaceuticals

22.62
-0.3700-1.61%
Volume:1.33M
Turnover:30.33M
Market Cap:3.82B
PE:17.06
High:23.05
Open:22.99
Low:22.55
Close:22.99
52wk High:26.65
52wk Low:13.40
Shares:168.71M
Float Shares:115.85M
Volume Ratio:0.81
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.33
EPS(LYR):1.37
ROE:33.18%
ROA:5.27%
PB:4.64
PE(LYR):16.55

Loading ...

ACADIA Pharmaceuticals Advances Phase 3 Study for Lewy Body Dementia Psychosis Treatment

TIPRANKS
·
Yesterday

Does the Halted Carbetocin Trial and Investigation Shift the Growth Outlook for ACADIA Pharmaceuticals (ACAD)?

Simply Wall St.
·
Oct 23

This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Benzinga_recent_news
·
Oct 21

ACADIA Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
Oct 21

ACADIA Pharmaceuticals Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $33

THOMSON REUTERS
·
Oct 21

ACADIA Pharmaceuticals: Hold Rating Amid Pipeline Shifts and Product Focus

TIPRANKS
·
Oct 20

ACADIA Pharmaceuticals Inc. to Release Third Quarter 2025 Financial Results

Reuters
·
Oct 16

ACADIA Pharmaceuticals (ACAD) Receives a Buy from RBC Capital

TIPRANKS
·
Oct 09

RBC Cuts Price Target on ACADIA Pharmaceuticals to $34 From $40, Keeps Outperform Rating

MT Newswires Live
·
Oct 08

U.S. RESEARCH ROUNDUP- AGCO, Caterpillar, United Rentals

Reuters
·
Oct 08

Mizuho Securities Remains a Hold on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Oct 08

Acadia Healthcare Appoints Todd Young as Chief Financial Officer, Effective October 2025

Reuters
·
Oct 08

Acadia Pharmaceuticals Announces New Clinical Data and Pipeline Updates at 2025 International Congress of Parkinson’s Disease and Movement Disorders

Reuters
·
Oct 02

J.P. Morgan Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Sep 30

ACADIA Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
Sep 29

U.S. RESEARCH ROUNDUP-Amazon, Insulet, Vertex

Reuters
·
Sep 29

ACADIA Pharmaceuticals Inc : JP Morgan Cuts Target Price to $33 From $34

THOMSON REUTERS
·
Sep 29

Acadia Pharmaceuticals Hit by Trial Failure for Prader-Willi Syndrome, Deutsche Bank Says

MT Newswires Live
·
Sep 25

Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $29 From $35, Maintains Buy Rating

MT Newswires Live
·
Sep 25

ACADIA Pharmaceuticals Inc : Bmo Cuts Target Price to $26 From $28

THOMSON REUTERS
·
Sep 25